Drug Database
Back to search

United States· US:0074-0561_5d893369-497c-46ee-9b64-ee737fab4225

Venclexta

A venetoclax product containing venetoclax, registered in United States by AbbVie Inc.. The same ATC class is registered in 14 of our 19 countries.

ATC L01XX52US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedVenclextaATCL01XX52REGISTER NO.US:0074-0561_5d893369…PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about venetoclaxAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Venetoclax is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XX52 (venetoclax), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose
Search venetoclax products by name

Venetoclax · ATC L01XX52

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of venetoclax costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $226.72 in Switzerland to $1527.13 in France — a ×6.7 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Venetoclax · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • FR France$1527.13
  • CH Switzerland$226.72
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
VENETOCLAX
Manufacturer
AbbVie Inc.
Country
United States (US)
ATC code
L01XX52
ATC class
Venetoclax
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 4

  • ndc11
    0074056111
    1 BLISTER PACK in 1 CARTON (0074-0561-11) / 2 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0074056114
    1 BLISTER PACK in 1 CARTON (0074-0561-14) / 14 TABLET, FILM COATED in 1 BLISTER PACK
  • ndc11
    0074-0561-11
  • ndc11
    0074-0561-14

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

338 interactions on record for venetoclax.

Graded by severity as the source publishes them — 168 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check venetoclax against other medicinesHow interaction checks work

Venetoclax · interactions on record

338 records

  • 168 severe
  • 168 moderate
  • 2 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • RolapitantA04AD14severe
  • FidaxomicinA07AA12severe
  • EliglustatA16AX10severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Venetoclax in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All venetoclax products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Venclyxto
  • Iceland · Venclyxto
  • Liechtenstein · Venclyxto
  • Norway · Venclyxto

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eea7e391-702c-4983-b53d-3c28acca33f8
GET /v1/drugs/eea7e391-702c-4983-b53d-3c28acca33f8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "10",
  "substance": "VENETOCLAX",
  "productndc": "0074-0561",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA208573",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about venetoclax.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console